Safety, Tolerability, Pharmacokinetics, and Antitumour Activity of SHR-A1811, in Patients With HER2-expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: a Phase 1 Study
Latest Information Update: 22 Mar 2024
Price :
$35 *
At a glance
- Drugs Trastuzumab rezetecan (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 19 Mar 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 19 Mar 2024 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
- 19 Mar 2024 Status changed from recruiting to active, no longer recruiting.